Bcl-2家族抑制剂使人类癌症模型对治疗敏感
Elisabetta Valentini1, Marta Di Martile2, Matteo Brignone1
1Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Cell death & disease
|July 17, 2023
概括
像IS21这样的BH3模仿剂,通过向抗亡蛋白质,在癌症治疗中表现有前途. 将这些药物与现有治疗方法结合起来,可以提高它们在各种癌症中的有效性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- BH3模仿剂向BCL-2家族的抗亡蛋白,为癌症提供治疗策略.
- ABT-199,一种Bcl-2抑制剂,是FDA批准用于血液恶性瘤.
- IS21是一种具有临床前抗瘤活性的新型泛BH3模仿剂.
研究的目的:
- 评估IS21和其他BH3模仿剂作为单一药物和组合疗法的疗效.
- 调查Bcl-xL和Mcl-1蛋白水平对IS21敏感性的预测值.
- 阐明IS21在癌症细胞系中的作用机制.
主要方法:
- 在T细胞急性淋巴细胞白血病,卵巢癌和黑色素瘤细胞系中对IS21和BH3模仿物的查.
- 评估Bcl-xL和Mcl-1蛋白水平对IS21敏感性的影响.
- 通过蛋白质复合体分析研究IS21的作用机制.
- 与化疗,PARP抑制剂和MAPK抑制剂的联合研究.
主要成果:
- IS21在多个癌症细胞系中表现出活性,包括T细胞急性淋巴细胞白血病,黑色素瘤,肺癌,胰腺癌和卵巢癌.
- Bcl-xL和Mcl-1水平分别预测了黑色素瘤和卵巢癌中的IS21敏感性.
- IS21的有效性取决于BAX和BAK蛋白质,减少Bcl-2/Bcl-xL复合体.
- BH3模仿了对化疗敏感的白血病细胞和对向抑制剂的固体瘤,从而增强了细胞亡.
结论:
- 抗亡蛋白的抑制剂,如IS21,作为单一疗法和联合治疗有效.
- 预测生物标志物如Bcl-xL和Mcl-1水平可以指导使用BH3模仿剂.
- BH3模仿剂通过在血液和固体瘤中强化亡来增强标准抗癌治疗的疗效.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Tumor Immunotherapy
567
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
567
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


